Instead of criticizing foreign deals, we should be talking about corporate-tax reform to bring business—and jobs—back to the US, says Jake Novak.
AstraZeneca told Pfizer its final offer isn't good enough. Mark Schoenebaum, ISI Group biotech & pharma analyst, provides insight to the potential deal.
As AstraZeneca's shares slid following its rejection of Pfizer's new bid, the company's chairman said he was "reasonably confident" it was the right decision.
Execution risk and the disruptive element of Pfizer's offer on AstraZeneca's pipeline were also taken into consideration before rebuffing the U.S. giant, Leif Johansson, chairman at AstraZeneca, tells CNBC.
Activist investor William Ackman told Allergan's board that the CEO has a 'disabling' conflict of interest because a takeover means losing his job.
AstraZeneca has rejected Pfizer's final offer of about $117,000 billion. CNBC's Meg Tirrell says the drug maker has no plans to go hostile.
Leif Johansson, AstraZeneca's chairman, says the group engaged with shareholders before rejecting Pfizer's offer and included their price conditions for a deal after "very strong feedback" from shareholders.
Chinese police have charged several former GlaxoSmithKline employees as the British drug maker is accused of evading million in Chinese taxes.
What we have found is that you are more productive when you have focus teams working on targets, says Scott Gottlieb, American Enterprise Institute, sharing his thoughts on big pharma deals and why they may reduce innovation and competition in the space.
Savvas Neophytou, pharmaceutical analyst at Panmure Gordon, says the probability of any further move from Pfizer on AstraZeneca has been greatly reduced as both groups disagree on the value of AstraZeneca's pipeline.
While AstraZeneca's management has rejected Pfizer's latest offer, there is still "some wriggle room." However, six months are needed before another offer can be brought forward, CNBC's Catherine Boyle reports.
Mick Cooper, health care analyst at Edison Investment Research, says that AstraZeneca is under a lot of pressure to deliver after it rejected Pfizer - which could come back in another six months.
It's new, it's undoubtedly deadly. But is MERS creating too much panic? That may be the case, says one expert.
You just might want to pay attention to the latest health insurance jargon. It could mean thousands of dollars out of your pocket.
Some 1,400 Kaiser pharmacist may go on strike Monday, an event that could displace more than 3 million people insured by the firm—OC Register.
The U.K.'s takeover regulations should change so that the government can stop Pfizer taking over AstraZeneca if it wants to, an influential group of U.K. MPs has said.
CNBC's Meg Tirrell reports on the latest cancer study data ahead of the big American Society of Clinical Oncology meeting in a couple of weeks.
CNBC's Catherine Boyle comments on the latest developments in the GSK bribery investigation in China and on the second day of hearings for Pfizer and AstraZeneca's CEOs.
Chinese police on Wednesday said they had charged the British former China head of drugmaker GlaxoSmithKline and other colleagues with corruption, after a 10- month probe found they paid billions of yuan in bribes to doctors and hospitals.
Raghuram Selvaraju, Head of Healthcare Equity Research at Aegis Capital, outlines reasons why Pfizer will likely to seize control of U.K rival AstraZeneca.